Here's Why We're Not At All Concerned With RxSight's (NASDAQ:RXST) Cash Burn Situation
Peeling Back The Layers: Exploring RxSight Through Analyst Insights
Needham Maintains RxSight(RXST.US) With Buy Rating, Maintains Target Price $66
Needham analyst David Saxon maintains $RxSight(RXST.US)$ with a buy rating, and maintains the target price at $66.According to TipRanks data, the analyst has a success rate of 34.7% and a total
RxSight's Growth Trajectory: A Buy Recommendation on Strong Revenue Prospects and International Expansion
Three 'Buys,' Three 'Sells,' and a 'Hold,' by Oppenheimer Analysts
Morgan Stanley Maintains RxSight(RXST.US) With Buy Rating, Maintains Target Price $70
Morgan Stanley analyst Patrick Wood maintains $RxSight(RXST.US)$ with a buy rating, and maintains the target price at $70.According to TipRanks data, the analyst has a success rate of 61.9% and a
Companies Like RxSight (NASDAQ:RXST) Can Afford To Invest In Growth
RxSight, Inc. to Participate in Upcoming Morgan Stanley and Wells Fargo Healthcare Conferences
Needham Maintains Buy on RxSight, Raises Price Target to $66
RxSight Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Hims & Hers Health (HIMS) and RxSight (RXST)
Needham Maintains RxSight(RXST.US) With Buy Rating, Raises Target Price to $66
Needham analyst David Saxon maintains $RxSight(RXST.US)$ with a buy rating, and adjusts the target price from $54 to $66.According to TipRanks data, the analyst has a success rate of 35.3% and a
Express News | Rxsight Inc : Needham Raises Target Price to $66 From $54
Does RxSight (RXST) Have the Potential to Rally 27.64% as Wall Street Analysts Expect?
US$63.00: That's What Analysts Think RxSight, Inc. (NASDAQ:RXST) Is Worth After Its Latest Results
Deep Dive Into RxSight Stock: Analyst Perspectives (6 Ratings)
Lithia Motors To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Tuesday
Earnings Call: RxSight Sees Robust Growth With LAL Sales and Raised Guidance
Oppenheimer Maintains RxSight(RXST.US) With Buy Rating, Cuts Target Price to $65
Oppenheimer analyst Steven Lichtman maintains $RxSight(RXST.US)$ with a buy rating, and adjusts the target price from $72 to $65.According to TipRanks data, the analyst has a success rate of 52.4%
A Quick Look at Today's Ratings for RxSight(RXST.US), With a Forecast Between $54 to $70
On Aug 06, major Wall Street analysts update their ratings for $RxSight(RXST.US)$, with price targets ranging from $54 to $70.Morgan Stanley analyst Patrick Wood maintains with a buy rating, and